Panelists discuss how bronchiectasis is more common than previously thought, with growing awareness, research, and specialized centers improving diagnosis and treatment options, though challenges remain in standardizing care and securing insurance coverage for therapies.
Clinical Brief: Unmet Needs in Bronchiectasis Management
Main Discussion Topics
Key Points for Physicians
Notable Insights
The panel emphasized that bronchiectasis is not a rare disease, as previously thought, but is rather common and significantly impacts quality of life, making investment in better detection and management crucial.
Clinical Significance
Despite recent advances, substantial unmet needs remain in bronchiectasis management, creating opportunities for research and clinical practice improvement to reduce the significant burden of this disease.
Using AI, Socioeconomic Factors to Predict Outcomes After Allo-SCT for AML
August 16th 2025Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease progression.
Read More